Compare UE & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UE | SLBT |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Taiwan |
| Employees | 104 | 20 |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.4B |
| IPO Year | 2014 | N/A |
| Metric | UE | SLBT |
|---|---|---|
| Price | $23.56 | $3.86 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 236.9K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 3.91% | N/A |
| EPS Growth | ★ 23.33 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $471,935,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.12 | N/A |
| P/E Ratio | $130.67 | ★ N/A |
| Revenue Growth | ★ 6.06 | N/A |
| 52 Week Low | $18.46 | $3.23 |
| 52 Week High | $24.11 | $6.25 |
| Indicator | UE | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 58.99 | 44.13 |
| Support Level | $18.69 | $3.40 |
| Resistance Level | $23.71 | $4.91 |
| Average True Range (ATR) | 0.36 | 0.64 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 72.56 | 1.22 |
Urban Edge Properties is a real estate investment trust principally focused on the management and development of retail real estate properties in urban communities in the U.S. Having originally been created to hold the majority of Vornado Realty Trust's shopping center businesses, Urban Edge's asset portfolio is mostly composed of shopping centers and malls in terms of total square footage. The company's holdings include necessity and convenience-oriented retailers, such as department stores, grocers, health clubs, and restaurants. Urban Edge's properties are mainly located in the New York City metropolitan region and within the DC to Boston corridor. The company generates nearly all of its revenue through the collection of rent from a large number of tenants.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.